Patents Assigned to Applied Research Systems ARS
-
Publication number: 20120040933Abstract: piperazine compounds for use as pharmaceutically active compounds and in pharmaceutical formulations that are useful for the treatment of disorders associated with apoptosis, including neurodegenerative disorders, diseases associated with polyglutamine tracts, epilepsy, ischemia, infertility, cardiovascular disorders, renal hypoxia, hepatitis and AIDS, where the piperazine compounds are represented by formula (I) and the terms R0, R1, R2, R3, k, l, m, n, and X are defined herein:Type: ApplicationFiled: September 6, 2011Publication date: February 16, 2012Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Serge HALAZY, Dennis Church, Bruno Antonsson, Agnes Bombrun, Patrick Gerber, Jean-Claude Martinou
-
Publication number: 20110263628Abstract: The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.Type: ApplicationFiled: June 8, 2011Publication date: October 27, 2011Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Dominique Swinnen, Agnes Bombrun, Jerome Gonzalez, Stefano Crosignani, Patrick Gerber, Catherine Jorand-Lebrun
-
Publication number: 20110034458Abstract: The present invention is related to pyridine methylene azolidinone derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.Type: ApplicationFiled: October 18, 2010Publication date: February 10, 2011Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Thomas RUECKLE, Anna Quattropani, Vincent Pomel, Jerome Dorbais, David Covini, Alexander Bischoff
-
Publication number: 20100168101Abstract: The present invention is related to the use of oxindole hydrazide derivatives of formula (I) for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of oxindole hydrazide derivatives of formula (I) to modulate, notably to inhibit the activity of PTPs, in particular of PTP1B, TC-PTP, SHP and GLEPP-1. The present invention is furthermore related to novel oxindole hydrazide derivatives and method of preparation thereof.Type: ApplicationFiled: December 23, 2009Publication date: July 1, 2010Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Agnes BOMBRUN, Patrick Gerber, Dennis Church
-
Publication number: 20090317380Abstract: The use of Apolipoprotein B, Apoliporpotein E, fragments and mimetics thereof is provided for diagnostic, detection, prognostic and therapeutic applications in prion diseases. More specifically, the invention provides the use of Apolipoprotein B or fragments thereof for modulating or identifying modulators of the prion protein replication which are implicated in the pathogenesis of transmissible spongiform encephalopathies and other prion diseases.Type: ApplicationFiled: August 27, 2009Publication date: December 24, 2009Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Claudio SOTO-JARA, Kinsey Maundrell
-
Publication number: 20090298055Abstract: The present invention is of a method of producing proteins in mammalian cells using a permanent selection in the absence of cytotoxic drugs. Specifically, the present invention can be used to produce large quantities of highly pure human proteins which are suitable for pharmaceutical applications.Type: ApplicationFiled: November 28, 2005Publication date: December 3, 2009Applicant: Applied Research Systems ARS Holding S.A.Inventors: Yehuda Assaraf, Lilac Rothem
-
Publication number: 20090216008Abstract: A method of preparing 21-hydroxy-6,19-oxidoprogesterone, or an acylated or phosphorlated version thereof.Type: ApplicationFiled: February 9, 2009Publication date: August 27, 2009Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Gerardo BURTON, Carlos P. Lantos, Adriana Silvia Veleiro
-
Publication number: 20090029998Abstract: The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.Type: ApplicationFiled: January 11, 2005Publication date: January 29, 2009Applicant: APPLIED RESEARCH SYSTEM ARS HOLDING N.V.Inventors: Anna Quattropani, Thomas Rueckle, Matthias Schwarz, Jerome Dorbais, Wolfgang Sauer, Christophe Cleva, Gwenaelle Desforges
-
Publication number: 20090022657Abstract: Novel antagonists of the chemokine CXCL8 (also known as Interleukin-8) can be obtained by generating mutants having specific combinations of non-conservative substitutions of basic amino acids located in the C-terminal region. Compounds prepared in accordance with the present invention can be used to block CXCL8 activity in vivo, thereby providing therapeutic compositions for use in the treatment or prevention of CXCL8-related diseases.Type: ApplicationFiled: October 22, 2004Publication date: January 22, 2009Applicant: Applied Research Systems ARS Holding N.V.Inventors: Amanda Proudfoot, Jeffrey Shaw
-
Publication number: 20080286227Abstract: The invention relates to the use of IL-17F, or of an agonist of IL-17F activity, for treatment or prevention of neurologic diseases.Type: ApplicationFiled: September 21, 2005Publication date: November 20, 2008Applicant: Applied Research Systems ARS Holding N.V.Inventors: Yves Sagot, Sandrine Pouly
-
Publication number: 20080269227Abstract: The present invention is related to fused pyridine methylene azolidinone derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.Type: ApplicationFiled: September 2, 2005Publication date: October 30, 2008Applicant: APPLIED RESEARCH SYSTEM ARS HOLDING N.V.Inventors: Thomas Rueckle, Anna Quattropani, Vincent Pomel, Jerome Dorbais, David Covini, Alexander Bischoff
-
Publication number: 20080255222Abstract: The present invention relates to benzsulfonamide derivatives of formula I and methods of use thereof. The benzsulfonamide derivatives of the present invention are efficient modulators of the JNK pathway. In particular the benzsulfonamide derivatives of the present invention are selective inhibitors of JNK 2 and 3.Type: ApplicationFiled: June 19, 2008Publication date: October 16, 2008Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Serge HALAZY, Dennis Church, Stephen J. Arkinstall, Marco Biamonte, Montserrat Camps, Jean-Pierre Gotteland, Thomas Rueckle
-
Patent number: 7419999Abstract: 1,2-substituted 5-pyrrolidinone compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, renal dysfunction, an immune deficiency disorder, dry eye, ichthyosis, elevated intraocular pressure, sleep disorder, or gastric ulcer, inflammatory disorders and other diseases and disorders associated with the prostaglandin family of compounds.Type: GrantFiled: June 9, 2003Date of Patent: September 2, 2008Assignee: Applied Research Systems ARS Holding N.V.Inventors: Gian Luca Araldi, Adulla P. Reddy, Zhong Zhao, Sean D. McKenna, Bagna Bao
-
Patent number: 7407651Abstract: Interferon-beta liquid formulations stabilized with a polyol, a non-reducing sugar or a amino acid. In particular, the formulations are stabilized with a polyol, such as mannitol. The formulations, preferably, furthermore comprise a buffer, such as acetate buffer, at a pH comprised between 3.0 and 4.0 and human albumin at a minimum quantity. The interferon-beta is preferably recombinant.Type: GrantFiled: July 16, 2004Date of Patent: August 5, 2008Assignee: Applied Research Systems ARS Holding NVInventors: Fabrizio Samaritani, Patrizia Natale
-
Publication number: 20080167318Abstract: The present invention is related to pyrrolidine derivatives of formula I. Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula I are useful in the treatment and/or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin, including premature labor, premature birth and dysmenorrhea. The present invention is furthermore related to novel pyrrolidine derivatives as well as to methods of their preparation.Type: ApplicationFiled: April 9, 2007Publication date: July 10, 2008Applicant: APPLIED RESEARCH SYSTEM ARS HOLDING N.V.Inventors: Serge Halazy, Anna Quattropani, Alexander Scheer, Matthias Schwarz, Russell J. Thomas, Anthony Baxter
-
Publication number: 20080146806Abstract: The present invention is related to octahydropyrrolo[2,3,c]pyridine derivatives of Formula (I) and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.Type: ApplicationFiled: July 20, 2005Publication date: June 19, 2008Applicant: Applied Research Systems ARS Holding N.V.Inventors: Dominique Swinnen, Agnes Bombrun
-
Publication number: 20080107621Abstract: The present invention relates to the use of IL-6 or a fragment, variant, fusion protein, functional derivative or salt thereof in microvascular complications.Type: ApplicationFiled: August 30, 2005Publication date: May 8, 2008Applicants: APPLIED RESEARCH SYSTEMS ARS HOLDING S.A., LABORATOIRES SERONO SAInventors: Michel Dreano, Pierre-Alain Vitte, Norman Cameron, Mary A. Cotter
-
Publication number: 20080108849Abstract: The present invention is related to a new synthesis for preparing para-phenyl alkynyl benzaldehyde of general formula (I). The compounds of formula (1) are useful building blocks, in particular in the synthesis of electrically conducting polymers. R is selected from the group consisting of C1-C12-alkyl, C1-C12-alkyl aryl, C1-C12-alkyl heteroaryl, C2-C12-alkenyl, C2C12-alkenyl aryl, C2-C12-alkenyl heteroaryl, C2-C12-alkynyl, C2-C12-alkynyl aryl, C2-C12-alkynyl heteroaryl, C3-C8-cycloalkylC1-C12--alkyl-C3-C8-cycloalkyl, C1-C12-alkoxy, aryl, heteroaryl, halides.Type: ApplicationFiled: October 12, 2004Publication date: May 8, 2008Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.Inventors: Dominique Swinnen, Danig Pohin
-
Patent number: 7364910Abstract: The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulators include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase 4 isoforms.Type: GrantFiled: July 6, 2006Date of Patent: April 29, 2008Assignee: Applied Research Systems ARS Holding N.V.Inventors: Stephen Palmer, Sean McKenna, Mark Tepper, Aliza Eshkol, Michael C. MacNamee
-
Publication number: 20080091358Abstract: Utilization of genomic markers from whole-genome scans or gene association studies from one or more related disease/genetics publications to determinate possible single or average contribution of any gene to marker scores. The invention includes the ability to use multiple data sets from multiple publications to consider broader pools of genes as well as more accurately linking genes to a particular trait. The method includes algorithms to create scores to rank genes related to particular traits. The scores help a researcher determine genes that are the most promising to send through a more rigorous, time-consuming and expensive in vitro and/or in vivo trial program.Type: ApplicationFiled: December 14, 2005Publication date: April 17, 2008Applicant: Applied Research Systems ARS Holcing, N.V.Inventor: Deanne Taylor